Biocon Biologics obtains USFDA approval for biosimilar Aflibercept
Yesafili enters U.S. market to treat ophthalmology conditions
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
YESAFILI
Biocon Biologics gets MHRA approval for YESAFILI, biosimilar Aflibercept
In September, YESAFILI received marketing authorisation approval from the European Commission (EC) for the European Union (EU)
Biocon Biologics gets EC approval for YESAFILI, biosimilar Aflibercept
The EC decision follows the European Medicines Agency’s CHMP positive opinion recommending approval of YESAFILI in July
Biocon Biologics gets positive CHMP opinion for YESAFILI, biosimilar Aflibercept
YESAFILI is intended for the treatment of neovascular age-related macular degeneration, visual impairment due to macular oedema…